InstaPILL
Bengaluru, India· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A leading Indian CDMO specializing in proprietary lyophilized orally disintegrating tablet technology for patient-centric drug delivery.
Central Nervous SystemGastroenterologyAllergy & ImmunologyPsychiatry
Technology Platform
Proprietary lyophilization (freeze-drying) technology platform for manufacturing porous, rapidly dissolving Orally Disintegrating Tablets (ODTs) that disintegrate in 3-10 seconds without water.
Opportunities
Growing global demand for patient-centric dosage forms to improve medication adherence in pediatric, geriatric, and dysphagic populations, and the trend for pharma companies to outsource complex formulation development to specialized CDMOs.
Risk Factors
Dependence on the pharmaceutical outsourcing market, concentration risk in a single technology platform (lyophilized ODTs), and intense competition from other CDMOs and large pharma with internal capabilities.
Competitive Landscape
Competes with other ODT-focused CDMOs (e.g., companies like Aprecia, Catalent's Zydis platform) and large pharma's internal units. Differentiation lies in its high-capacity, automated lyophilization facility, extensive taste-masking expertise, and regulatory approvals for all major markets.